

CONTENTS

List of Tables	VIII
List of Figures	X
List of Abbreviations	XIII
Research publications	XIV

Title	Page No.
CHAPTER 1: INTRODUCTION	
1.1 RESEARCH ENVISAGED	6
1.2 REFERENCES	7
CHAPTER 2: LITERATURE REVIEW	
2.1 HUMAN RESPIRATORY SYSTEM	12
2.1.1 Anatomy of Airways	12
2.1.2 Pulmonary Ventilation	13
2.1.3 Pulmonary Clearance	13
2.1.4 Mucociliary Clearance	15
2.1.5 Pulmonary Endocytosis	15
2.1.6 Pulmonary Absorption	16
2.2 DRUG DELIVERY TO THE AIRWAYS	17
2.2.1 Deposition Mechanisms	17
2.2.1.1 Impaction	17
2.2.1.2 Sedimentation	17
2.2.1.3 Brownian Diffusion and Electrostatic Attraction	18
2.2.2 Factors Controlling Deposition	18
2.2.2.1 Particle Characteristics	18
2.2.2.2 Airway Geometry	19
2.2.2.3 Breathing Pattern	19
2.2.2.4 Hygroscopic Growth	20
2.2.3 Assessments of Airway Deposition	20
2.2.3.1 Pharmacokinetic Methods	20
2.2.3.2 Modeling	21
2.2.3.3 Photometry and Filter Collection	21

	2.2.3.4	Bronchoalveolar Lavage	22
	2.2.3.5	Radioactivity	22
	2.2.3.6	Magnetopneumography	24
2.3		DRUG DELIVERY SYSTEMS	24
	2.3.1	Nebulizers	25
	2.3.2	Pressurized Metered Dose Inhalers	25
	2.3.3	Dry Powder Inhalers	25
	2.3.4	Factors Influencing Dry Powder Inhalers Formulation Design	26
		2.3.4.1 Physical Properties of Powders	26
		2.3.4.2 Drug Carrier	28
		2.3.4.3 Particle Engineering	29
		2.3.4.4 Metering Design	30
		2.3.4.5 Flow Path Design	31
	2.3.5	Regulatory and Pharmacopoeial Requirements	33
2.4		CYSTIC FIBROSIS	34
	2.4.1	Pathophysiology	35
	2.4.2	Therapeutic Approaches	37
		2.4.2.1 Therapies Directed at Inflammation	37
		2.4.2.2 Controlling Infection	39
		2.4.2.3 Reducing Airway Obstruction	39
		2.4.2.4 Nutrition	40
		2.4.2.5 Therapies Directed at the Basic Defect	40
		2.4.2.6 Lung Transplant	41
2.5		AEROSOLIZED ANTIBIOTICS IN CYSTIC FIBROSIS	42
	2.5.1	Challenges in Aerosolized Antibiotics Administration in Cystic Fibrosis	43
2.6		STRATEGIES FOR ENGINEERED DRY POWDER AEROSOL FORMULATIONS	44
	2.6.1	Use of Crystalline Instead of Amorphous Materials	44
	2.6.2	Use of Suitable Excipients in Blend Formulations	45
		2.6.2.1 Fine Particle Excipient	45
		2.6.2.2 Ternary Additive with Lubricant or Anti-	45

	adherent Properties	
2.6.3	Use of Particles with Designed Features	46
2.6.3.1	Co-spray Drying with a Suitable Excipient	46
2.6.3.2	Wrinkled Particles	46
2.6.3.3	Large Porous Particles	46
2.6.3.4	Pulmospheres and Pulmosols	47
2.7	EMERGING POWDER PRODUCTION METHODS	48
2.7.1	Spray Drying and Related Droplet Evaporation Methods	48
2.7.1.1	Spray Drying	48
2.7.1.2	Freeze Drying	49
2.7.1.3	Spray Freeze Drying	49
2.7.1.4	Controlled Evaporation of Droplets	50
2.7.1.5	Evaporation of Low-Boiling-Point Solutions	50
2.7.2	Solvent precipitation	50
2.7.2.1	Sono-crystallization	50
2.7.2.2	Microprecipitation by opposing liquid jets	50
2.7.2.3	Supercritical fluid (SCF) technology	51
2.7.3	Specialized Milling	51
2.7.3.1	Fluid Energy Milling at Elevated Humidity	51
2.7.3.2	Wet Milling Nanotechnology	51
2.8	AERODYNAMICALLY LIGHT AND LARGE PARTICLES	52
2.8.1	Density and Size of Aerodynamically Light and Large Particles	52
2.8.1.1	Particle Size	52
2.8.1.2	Particle Density and Deposition	53
2.8.2	Aerodynamically Light and Large Particles Composition	53
2.8.2.1	Surfactants/Co-surfactants	54
2.8.2.2	Anti-adherents	55
2.8.2.3	Polymers and Rigidifying agents	56
2.8.3	Formation of Aerodynamically Light and Large Particles	57
2.9	DEVELOPMENT OF DRY POWDER INHALATION FORMULATION	58
2.10	DRUG PROFILES	61

2.10.1	Tobramycin sulfate	61
2.10.1.1	Physico-chemical Properties	61
2.10.1.2	Pharmacology and Pharmacokinetics	61
2.10.1.3	Therapeutic use	63
2.10.1.4	Adverse effects	63
2.10.1.5	Methods for Estimation	64
2.10.2	Amikacin sulfate	65
2.10.2.1	Physico-chemical Properties	65
2.10.2.2	Pharmacology and Pharmacokinetics	65
2.10.2.3	Therapeutic Use	66
2.10.2.4	Adverse Effects	67
2.10.2.5	Methods for Estimation	68
2.11	REFERENCES	69
CHAPTER 3: ANALYTICAL METHODS		
3.1	INTRODUCTION	84
3.2	MATERIALS AND EQUIPMENTS	84
3.3	PHYSICAL ANALYSIS	85
3.3.1	Determination of Particle Size and Polydispersity	85
3.3.2	Determination of Tap Density	86
3.3.3	Determination of Moisture Content	86
3.3.4	Determination of Crystallinity	87
3.3.5	Characterization of Morphological Features	87
3.4	CHEMICAL ANALYSIS	88
3.4.1	Estimation of Phosphatidyl Choline	88
3.4.1.1	Solutions	88
3.4.1.2	Procedure for calibration curve	88
3.4.1.3	Stability and selectivity	89
3.4.1.4	Estimation of Phosphatidyl Choline from Formulation	89
3.4.2	Estimation of 6-coumarin	90
3.4.2.1	Procedure for Calibration Curve	90
3.4.2.2	Estimation of 6-coumarin from Formulation	91
3.4.3	Estimation of Tobramycin	91

3.4.3.1	Procedure for Calibration Curve	92
3.4.3.2	Stability and Selectivity	92
3.4.3.3	Estimation of Tobramycin from Formulation	93
3.4.3.4	Estimation of Tobramycin from Biological Samples	93
3.4.3.5	Stability and Selectivity	94
3.4.3.6	Extraction Efficiency	94
3.4.4	Estimation of Amikacin	95
3.4.4.1	Procedure for Calibration Curve	96
3.4.4.2	Stability and Selectivity	96
3.4.4.3	Estimation of Amikacin from Formulation	97
3.4.4.4	Estimation of Amikacin from Biological Samples	97
3.4.4.5	Stability and Selectivity	97
3.4.4.6	Extraction Efficiency	97
3.5	RESULTS AND DISCUSSION	99
3.5.1	Estimation of Phosphatidyl Choline	99
3.5.2	Estimation of 6-coumarin	100
3.5.3	Estimation of Tobramycin sulfate	100
3.5.4	Estimation of Amikacin sulfate	101
3.6	REFERENCES	103
CHAPTER 4: PREPARATION AND CHARACTERIZATION OF AERODYNAMICALLY LIGHT AND LARGE PARTICLES		
4.1	INTRODUCTION	104
4.2	MATERIALS	105
4.3	PREPARATION OF AERODYNAMICALLY LIGHT AND LARGE PARTICLES	105
4.4	OPTIMIZATION OF FORMULATION COMPONENTS	108
4.5	CHARACTERIZATION OF AERODYNAMICALLY LIGHT AND LARGE PARTICLES	110
4.5.1	Determination of Particle Size and Polydispersity	110
4.5.2	Determination of Tap Density	111
4.5.3	Determination of Moisture Content	111

4.5.4	Determination of Crystallinity	111
4.5.5	Characterization of Morphological Features	112
4.5.6	Drug Assay	112
4.5.6.1	Estimation of Tobramycin sulfate	112
4.5.6.2	Estimation of Amikacin sulfate	113
4.5.7	Characterization of Aerosol Performance	113
4.6	RESULTS AND DISCUSSION	115
4.6.1	Preparation and Characterization of Spray and Freeze Dried Aerodynamically Light and Large Particles	115
4.6.2	Aerosolization properties of SD and FD ALLP	123
4.6.3	Optimization of Formulation Components of Aerodynamically Light and Large Particles Prepared By Spray Drying	126
4.7	REFERENCES	135
CHAPTER 5: POWDER PROPERTIES		
5.1	INTRODUCTION	136
5.2	METHODS	137
5.2.1	Effect of Humidity on Aerosolization of ALLP	137
5.2.2	Effect of Air Flow Rate on Aerosolization of ALLP	138
5.2.3	Particle Flow and Dispersion	140
5.3	RESULTS AND DISCUSSION	141
5.4	REFERENCES	149
CHAPTER 6: STABILITY TESTING OF AERODYNAMICALLY LIGHT AND LARGE PARTICLES		
6.1	INTRODUCTION	151
6.2	METHODS	152
6.3	STATISTICAL ANALYSIS AND DATA INTERPRETATION	152
6.4	RESULTS AND DISCUSSION	157
6.5	REFERENCES	164
CHAPTER 7: IN VIVO STUDIES		
7.1	INTRODUCTION	165
7.2	METHODS	166
7.2.1	Intratracheal Powder Administration	166

7.2.2	Assessment of Pulmonary Deposition	167
7.2.3	Pulmonary Clearance Study	167
7.2.4	Alveolar Macrophage Uptake Study	167
7.2.5	Assessment of Pulmonary Toxicity	167
7.2.6	Data and Statistical Analysis	168
7.3	RESULTS AND DISCUSSION	168
7.4	REFERENCES	179
CHAPTER 8: SUMMARY AND CONCLUSION		
8.1	SUMMARY	181
8.2	CONCLUSION	196